Clinical evaluation of a new antidepressant: G-33040.

Abstract

G-33040 was administered to 18 depressed patients in a general hospital setting. Of these, 15 ( 83%) were rated as being somewhat or much improved. It is of note that 2 of the 3 patients who did not respond to this medication were also resistant to other antidepressant therapy. Fourteen of our patients showed a small but noticeable decrease in manifest anxiety following administration of the drug. At the dosage used, no subjective side-effects were noted. There was no hypotensive effect and no urinary or blood changes. Elevation of total serum bilirubin from 0.80 to 1.20 mgm. % ( normal under 0.90) and elevation of prothrombin time from 13 sees. to 14 secs. ( control 12 secs.) was noted in one patient. However transaminase and cephalin flocculation remained normal and unchanged. It would appear that G-33040 is a safe and useful antidepressant in a general hospital setting.